Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors

References

• Glynne-Jones R, Northover JM, Cervantes A, group EGW. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5):v87–92.
   Google Scholar
• Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, 3rd, Thomas CR, Jr, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 2008;299:1914–21.
   PubMed Web of Science ®Google Scholar
• Bentzen AG, Guren MG, Wanderas EH, Frykholm G, Tveit KM, Wilsgaard T, et al. Chemoradiotherapy of anal carcinoma: Survival and recurrence in an unselected national cohort. Int J Radiat Oncol Biol Phys 2012;83:e173–80.
   PubMed Web of Science ®Google Scholar
• Vistad I, Cvancarova M, Fossa SD, Kristensen GB. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: How well do physicians’ assessments agree with those of their patients? Int J Radiat Oncol Biol Phys 2008;71:1335–42.
   PubMed Web of Science ®Google Scholar
• Allal AS, Sprangers MA, Laurencet F, Reymond MA, Kurtz JM. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer 1999;80:1588–94.
   PubMed Web of Science ®Google Scholar
• Jephcott CR, Paltiel C, Hay J. Quality of life after non- surgical treatment of anal carcinoma: A case control study of long-term survivors. Clin Oncol (R Coll Radiol) 2004;16: 530–5.
   PubMed Web of Science ®Google Scholar
• Welzel G, Hagele V, Wenz F, Mai SK. Quality of life outcomes in patients with anal cancer after combined radiochemotherapy. Strahlenther Onkol 2011;187:175–82.
   PubMed Web of Science ®Google Scholar
• Provencher S, Oehler C, Lavertu S, Jolicoeur M, Fortin B, Donath D. Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. Radiat Oncol 2010;5:41.
   PubMed Web of Science ®Google Scholar
• Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer 2010;116:822–9.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality- of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
   PubMed Web of Science ®Google Scholar
• Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer 2009;45:3017–26.
   PubMed Web of Science ®Google Scholar
• Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. The EORTC QLQ-C30 scoring manual, 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
   Google Scholar
• Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139–44.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools. Eur J Cancer 2010;46:479–94.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Fossa SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res 2006;15:791–800.
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: The QLQ = C30 (+ 3). J Clin Oncol 1998;16: 1188–96.
   PubMed Web of Science ®Google Scholar
• van de Poll-Franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 2011;47:667–75.
   PubMed Web of Science ®Google Scholar
• Burkett VS, Cleeland CS. Symptom burden in cancer survivorship. J Cancer Surviv 2007;1:167–75.
   PubMedGoogle Scholar
• Norton NJ. The perspective of the patient. Gastroenterology 2004;126:S175–9.
   Google Scholar
• Andreyev HJ, Wotherspoon A, Denham JW, Hauer-Jensen M.‘Pelvic radiation disease’: New understanding and new solutions for a new disease in the era of cancer survivorship. Scand J Gastroenterol 2011;46:389–97.
   PubMed Web of Science ®Google Scholar
• Bruheim K, Tveit KM, Skovlund E, Balteskard L, Carlsen E, Fossa SD, et al. Sexual function in females after radiotherapy for rectal cancer. Acta Oncol 2010;49:826–32.
   PubMed Web of Science ®Google Scholar
• Bruheim K, Guren MG, Dahl AA, Skovlund E, Balteskard L, Carlsen E, et al. Sexual function in males after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010;76:1012–7.
   PubMed Web of Science ®Google Scholar
• Lind H, Waldenstrom AC, Dunberger G, al-Abany M, Alevronta E, Johansson KA, et al. Late symptoms in long-term gynaecological cancer survivors after radiation therapy: A population-based cohort study. Br J Cancer 2011;105: 737–45.
   PubMed Web of Science ®Google Scholar
• Bruheim K, Guren MG, Skovlund E, Hjermstad MJ, Dahl O, Frykholm G, et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010;76:1005–11.
   PubMed Web of Science ®Google Scholar
• Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fossa S, et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 2009; 10:370–80.
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, et al. Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: A prospective, longitudinal study. Gynecol Oncol 2012;124:389–94.
   PubMed Web of Science ®Google Scholar
• McKenna SP. Measuring patient-reported outcomes: Moving beyond misplaced common sense to hard science. BMC Med 2011;9:86.
   PubMed Web of Science ®Google Scholar
• Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: A theoretical model. Soc Sci Med 1999;48:1507–15.
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, et al. Dose-painted intensity- modulated radiation therapy for anal cancer: A multi- institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012;82:153–8.
   PubMed Web of Science ®Google Scholar
• Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity- modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys 2012;83:1455–62.
   PubMed Web of Science ®Google Scholar
• Sogaard AJ, Selmer R, Bjertness E, Thelle D. The Oslo Health Study: The impact of self-selection in a large, population-based survey. Int J Equity Health 2004;3:3.
   PubMedGoogle Scholar